GlassScriptPhysician profile
Philip Gurecki
NPI 1811370869
$13,128.77
in general payments reported to CMS, 2019-2025
71 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,785 · 2022: $2,564 · 2023: $2,824 · 2024: $2,467 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,779.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.27 | 2021-2025 | |
| Pfizer INC. | $1,147.71 | 2021-2025 | |
| Amgen INC. | $864.74 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $803.17 | 2021-2025 | Farxiga, Fasenra, Airsupra |
| Novo Nordisk INC | $787.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $710.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $549.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $507.97 | 2021-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $469.63 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.87 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.63 | 2021-2024 | Xifaxan |
| Radius Health, INC. | $319.68 | 2021-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $305.44 | 2021-2025 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $294.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $291.92 | 2021-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Gurecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.